Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial

Published:2022-06-17 Issue:5 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Huang Xiaoyuan¹,Fan Ting²,Li Li³,Nian Xuanxuan¹⁴^ORCID,Zhang Jiayou¹⁴,Gao Xuefen²,Zhao Wei¹⁴,Chen Wei¹⁴,Zhang Zhaoqing⁵,Yao Zhihao⁵,Han Xixin¹⁴,Shi Jinrong¹⁴,Wang Ying¹⁴,Bian Haihe⁶,Shi Nianmin³,Li Xinguo¹⁴,Duan Kai¹⁴,Li Guohua²,Yang Xiaoming⁴⁷^ORCID

Affiliation:

1. Wuhan Institute of Biological Products Co. Ltd, Wuhan, China

2. Shanxi Provincial Centers for Disease Control and Prevention, Taiyuan, Shanxi, China

3. Chaoyang Center for Disease Control and Prevention, Taiyuan, Shanxi, China

4. National Engineering Technology Research Center of Combined Vaccines, Wuhan, Hubei, China

5. Qinyuan County Center for Disease Control and Prevention, Taiyuan, Shanxi, China

6. Quwo County Center for Disease Control and Prevention, Taiyuan, Shanxi, China

7. China National Biotec Group Company Limited, Beijing, China

Funder

Ministry of Science and Technology of the People’s Republic of China

Publisher

Informa UK Limited